Atai Life Sciences N.V. (ATAI): Market Cap to Earnings and Growth Ratio

Symbol and logo of brand atai (ATAI)

Atai Life Sciences N.V. (ATAI) develops innovative therapies for treatment-resistant psychiatric disorders, ensuring stability through broad coverage of the neuropsychiatric market. High scientific authority and a platform-based approach to treating addictions reinforce an operational base shielded from macroeconomic shocks. The valuation-to-earnings growth ratio confirms growth potential, with the 0.00 metric serving as the target level.

Atai Life Sciences N.V. (ATAI): Price/Earnings to Growth Multiple from 07/04/2022 to 09/26/2026

Analytical breakdowns for atai Life Sciences (ATAI)

- share price and consensus valuation forecast:
Fundamental company analysis:ATAI - atai Life Sciences Corp
Original product of atai.life

The assessment of Atai Life Sciences N.V. (ATAI) margin of safety is based on the PEG ratio, where values below one signal a fundamental undervaluation of the asset. The price action of the growth-weighted P/E helps identify potential for a breakout as psychedelic drugs advance to final trial stages and regulatory requirements for mental disorder therapies are expected to ease.